• The first tumor type examined was type 1 (microsatellite instability [MSI]–high, CpG island methylator phenotype [CIMP] –positive, positive for BRAF mutation, negative for KRAS mutation).
• The second tumor type examined was type 2 (microsatellite stable [MSS] or MSI-low, CIMP-positive, positive for BRAF mutation, negative for KRAS mutation).
• The third tumor type examined was type 3 (MSS or MSI low, non-CIMP, negative for BRAF mutation, positive for KRAS mutation).
• The fourth tumor type examined was type 4 (MSS or MSI-low, non-CIMP, negative for mutations in BRAF and KRAS).
• The fifth tumor type examined was (MSI-high, non-CIMP, negative for mutations in BRAF and KRAS).
• The researchers found that type four tumors were the most common.
• Patients with type 2 tumors had the highest disease-specific mortality rate. Patients with type 3 tumors also had a high disease-specific mortality rate.
• Patients with type 5 tumors had the lowest disease-specific mortality rate.
• The researchers concluded that molecular heterogeneity of colorectal cancer plays an important role in understanding and combating the disease.
More articles on gastroenterology:
Preparing for ICD-10 in gastroenterology
4 must-reads on hepatitis C treatments
5 gastroenterologists making headlines this week
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
